Ads
related to: dangers of glp 1 drugs- View Patient Stories
Watch Videos of Patient Stories
Today to Start Your T1D Journey.
- See the FAQs
Get the Answers to Frequently
Asked Questions Today.
- Talk to Your Doctor
Download the Discussion Guide
to Start the Conversation Today.
- View T1D Organizations
Stay Connected. Learn About
T1D Organizations Today.
- Join the Support Program
View Resources & Copay Assistance.
Terms & Conditions Apply.
- Get Screened Today
Discover the Importance of Early
Screening. Learn More Now.
- View Patient Stories
Search results
Results From The WOW.Com Content Network
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
GLP-1 medications are drugs that mimic the effects of the GLP-1 hormone, helping regulate blood sugar and reduce appetite. They are primarily used for managing type 2 diabetes but are also ...
Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like nausea and diarrhea. But new research confirms that more serious ...
Native GLP-1 is a peptide hormone with a half-life of two minutes because it is rapidly cleared by the enzyme dipeptidyl peptidase-4. [29] As a result, different GLP-1 agonist drugs are modified in various ways to extend the half-life, resulting in drugs that can be dosed multiple times per day, daily, weekly, or less often. [29]
Beside the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective effects. Unlike GIP, the action of GLP-1 is preserved in patients with type 2 diabetes. Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting in the 2000s.
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different health outcomes. The findings show benefits for brain and heart health ...
The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.
But Al-Aly was particularly struck by the drugs’ apparent neurologic effects when compared with the care patients would normally receive—that is, without a GLP-1.